journal article·2024-12-03

Hydrogel-Mediated Jamming of Exosome Communications That Counter Tumor Adaption in the Tumor Immune Microenvironment

Kejian Shi, Wenjiao Fu, Zeinab Farhadi Sabet, Jinmin Ye, Shijian Liang, Tao Liu, Qiaolin Liu, Mengyu Guo, Min You, Junguang Wu, Ru Bai, Ying Liu, Bin Hu, Xuejing Cui, Jiayang Li, Chunying Chen

ACS Nano· Volume 18· Issue 48
Publisher page

Abstract

Hypoxia, a common occurrence within solid tumors, can stimulate the dissemination of deceptive tumor exosomes, which function as communicative bridges and orchestrate the recruitment of various supportive cell types for enhanced tumor adaptability in a tumor immune microenvironment. Current nanotechnology provides us intelligent strategies to combat the hypoxic tumor microenvironment. However, once exposed to external stimuli, such as chemotherapy, tumor cells simultaneously release malignant signals to develop tumor migration and immunosuppression, posing challenges to clinical practice. Taking advantage of the membrane-targeting therapeutic strategy, the application of a self-assembled short peptide (PepABS- p y), affording hydrogels on tumor cell surfaces, can block exosome dissemination with fiber-like nanostructures and effectively limit the systemic adverse effects of traditional therapeutics. Moreover, PepABS- p y can attenuate the hypoxic tumor microenvironment in vivo by carrying an inhibitor of the hypoxic tumor-overexpressed CA IX enzyme, where hypoxia is also a crucial regulator to induce tumor exosomes and mediate intercellular communications within the immune system. Herein, its application on jamming exosome communications can target the T cell-related signaling pathway by regulating microRNAs in exosome cargoes and ultimately enhances CD8 + T cell infiltration and alleviates inflammatory monocytes at metastasis sites. Collectively, with the capability of blocking exosome dissemination, PepABS- p y can be applied as a promising tumor membrane-targeting therapeutic tool to counter tumor adaption within an immune microenvironment and further advance traditional chemotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety and CAS Center for Excellence in Nanoscience, New Cornerstone Science Laboratory, National Center for Nanoscience and Technology of China, Beijing 100190, People’s Republic of China

Sino-Danish College, Sino-Danish Center for Education and Research, University of Chinese Academy of Sciences, Beijing 100049, People’s Republic of China

Research Unit of Nanoscience and Technology, Chinese Academy of Medical Sciences, Beijing 100021, People’s Republic of China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Chinese Academy of Sciences

References (75)

Show source-provided references
1. 10.2174/1574888X1366618081611480910.2174/1574888X13666180816114809 ↗
2. 10.1691/ph.2019/952610.1691/ph.2019/9526 ↗
3. 10.5114/aoms.2016.6272310.5114/aoms.2016.62723 ↗
4. 10.1038/nri.2017.10310.1038/nri.2017.103 ↗
5. 10.1038/nrc306410.1038/nrc3064 ↗
6. 10.1038/s41578-021-00315-x10.1038/s41578-021-00315-x ↗
7. 10.1016/j.nantod.2018.06.00810.1016/j.nantod.2018.06.008 ↗
8. 10.1021/acs.accounts.8b0021410.1021/acs.accounts.8b00214 ↗
9. 10.1002/adma.20190433710.1002/adma.201904337 ↗
10. 10.1038/s41577-023-00836-210.1038/s41577-023-00836-2 ↗
11. 10.1158/0008-5472.CAN-22-190210.1158/0008-5472.CAN-22-1902 ↗
12. 10.3390/cancers1102013610.3390/cancers11020136 ↗
13. 10.1158/0008-5472.CAN-19-114710.1158/0008-5472.CAN-19-1147 ↗
14. 10.1186/s12943-019-0975-510.1186/s12943-019-0975-5 ↗
15. 10.3390/cancers1201017110.3390/cancers12010171 ↗
16. 10.1016/j.semcancer.2014.04.00910.1016/j.semcancer.2014.04.009 ↗
17. 10.1155/2014/17948610.1155/2014/179486 ↗
18. 10.1016/j.cmet.2021.09.00210.1016/j.cmet.2021.09.002 ↗
19. 10.1038/s41556-018-0256-310.1038/s41556-018-0256-3 ↗
20. 10.1111/jcmm.1483810.1111/jcmm.14838 ↗
21. 10.1016/j.canlet.2020.03.01710.1016/j.canlet.2020.03.017 ↗
22. 10.1016/j.canlet.2020.05.01810.1016/j.canlet.2020.05.018 ↗
23. 10.1038/s41388-018-0627-z10.1038/s41388-018-0627-z ↗
24. 10.1186/s12943-018-0869-y10.1186/s12943-018-0869-y ↗
25. 10.1038/s41388-019-0782-x10.1038/s41388-019-0782-x ↗
26. 10.1038/s41586-018-0392-810.1038/s41586-018-0392-8 ↗
27. 10.1186/s13046-020-01820-710.1186/s13046-020-01820-7 ↗
28. 10.1038/s41590-023-01443-y10.1038/s41590-023-01443-y ↗
29. 10.1038/s41590-022-01379-910.1038/s41590-022-01379-9 ↗
30. 10.1038/s41586-020-03045-210.1038/s41586-020-03045-2 ↗
31. 10.1016/j.cmet.2016.08.01110.1016/j.cmet.2016.08.011 ↗
32. 10.1016/j.imbio.2012.02.00210.1016/j.imbio.2012.02.002 ↗
33. 10.1016/j.ccell.2022.08.01210.1016/j.ccell.2022.08.012 ↗
34. 10.1038/s41590-018-0226-810.1038/s41590-018-0226-8 ↗
35. 10.1002/adfm.20200594110.1002/adfm.202005941 ↗
36. 10.1002/adfm.20200275910.1002/adfm.202002759 ↗
37. 10.1126/science.aaf362710.1126/science.aaf3627 ↗
38. 10.1002/adma.20130323310.1002/adma.201303233 ↗
39. 10.3390/ma1220332310.3390/ma12203323 ↗
40. 10.3390/molecules2403060310.3390/molecules24030603 ↗
41. 10.1039/b806410p10.1039/b806410p ↗
42. 10.1021/acsnano.1c0420610.1021/acsnano.1c04206 ↗
43. 10.1002/adma.20180501810.1002/adma.201805018 ↗
44. 10.1038/s41467-022-31579-810.1038/s41467-022-31579-8 ↗
45. 10.1002/adma.20160177610.1002/adma.201601776 ↗
46. 10.1039/C6CS00656F10.1039/C6CS00656F ↗
47. 10.1038/s41565-023-01401-710.1038/s41565-023-01401-7 ↗
48. 10.1002/anie.20140221610.1002/anie.201402216 ↗
49. 10.1002/adma.20160586910.1002/adma.201605869 ↗
50. 10.1038/s41565-019-0626-410.1038/s41565-019-0626-4 ↗
51. 10.1021/jacs.2c1182310.1021/jacs.2c11823 ↗
52. 10.1126/sciadv.aax093710.1126/sciadv.aax0937 ↗
53. 10.1186/s12943-015-0384-310.1186/s12943-015-0384-3 ↗
54. 10.1111/jcmm.1426510.1111/jcmm.14265 ↗
55. 10.1016/j.gpb.2015.02.00110.1016/j.gpb.2015.02.001 ↗
56. 10.3390/cancers1107096310.3390/cancers11070963 ↗
57. 10.1016/j.ccell.2022.01.00110.1016/j.ccell.2022.01.001 ↗
58. 10.1007/s13205-012-0113-110.1007/s13205-012-0113-1 ↗
59. 10.1016/S0002-9610(05)80512-410.1016/S0002-9610(05)80512-4 ↗
60. 10.1038/s41598-020-69622-710.1038/s41598-020-69622-7 ↗
61. 10.1016/0009-9120(87)90003-810.1016/0009-9120(87)90003-8 ↗
62. 10.1002/anie.20160075310.1002/anie.201600753 ↗
63. 10.1002/anie.20181455210.1002/anie.201814552 ↗
64. 10.1038/ncomms204010.1038/ncomms2040 ↗
65. 10.3389/fimmu.2022.82418810.3389/fimmu.2022.824188 ↗
66. 10.1038/ncomms1524210.1038/ncomms15242 ↗
67. 10.1038/nprot.2012.13510.1038/nprot.2012.135 ↗
68. 10.1158/0008-5472.CAN-17-384110.1158/0008-5472.CAN-17-3841 ↗
69. 10.1186/1479-5876-6-3710.1186/1479-5876-6-37 ↗
70. 10.1016/j.cell.2019.02.01610.1016/j.cell.2019.02.016 ↗
71. 10.1042/BST2012026510.1042/BST20120265 ↗
72. 10.18632/oncotarget.704110.18632/oncotarget.7041 ↗
73. 10.1016/j.bbrc.2017.08.10710.1016/j.bbrc.2017.08.107 ↗
74. 10.7150/thno.3442910.7150/thno.34429 ↗
75. 10.1038/nature1575610.1038/nature15756 ↗